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ABSTRACT
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of 
tumours that originate predominantly from the oral cavity, pharynx and larynx. Our 
aim was to determine whether salivary miRNA expression levels can diagnose these 
cancer subtypes. Saliva samples were collected from healthy controls (n=113, smoker 
and non-smokers), HPV-positive (n=54) and HPV-negative (n=47) HNSCC patients. 
The miRNA expression levels in saliva was quantified using qPCR. The potential 
of salivary miRNAs to discriminate these groups of patients was evaluated using 
multiple logistic regression with ROC analysis and a 10-fold cross-validation analysis. 
Salivary miRNA-9, -127, -134, -191, -222 and -455 were shown to discriminate a 
control group from a HPV-negative HNSCC patient group with a sensitivity of 60% 
and a specificity of 94%; whilst salivary miRNA-9,-134, -196b, -210, and -455 were 
the most parsimonious subset discriminating a control group from a HPV-positive 
HNSCC group, with a sensitivity of 65% and a specificity of 95%. Furthermore, 
miRNA-9, -134, -196b, -210 and -455 as a panel, was the most parsimonious subset 
to discriminate HPV-positive HNSCC patients from HPV-negative HNSCC patients. In 
addition, the expression levels of miRNA-9, -127, -196a, -196b, -210, -222 and -455 
were significantly increased in the saliva collected from early stage HNSCC patients 
compared to controls. A future multi-centre confirmatory study is warranted to test 
the diagnostic performance of these salivary miRNA prior to clinical implementation.
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INTRODUCTION
Head and neck cancers are a heterogeneous group 
of tumours that originate in the the nasal cavity, paranasal 
sinuses, oral cavity, salivary glands, pharynx and larynx 
[1–4]. A large number (>90%) of these malignancies 
are squamous cell carcinoma (SCC) that arise from the 
squamous epithelium of the oral cavity and the oropharynx 
[2, 5–7], they are generally referred to as head and neck 
squamous cell carcinomas (HNSCC). HNSCC currently 
stands as the sixth most common cancer worldwide with 
900,000 new cases per year, with about 300,000 deaths 
annually [1].
There is a rapid rise in the incidence of 
oropharyngeal cancers (OPC), a type of HNSCC, caused 
by the human papillomavirus type 16 (HPV-16) [8] in 
the USA and in the western world, whilst oral cavity 
cancer (OC, predominantly HPV-negative) prevalence 
is increasing in emerging economies [8–10]. In general, 
HPV-positive HNSCC patients have a better prognosis 
than HPV-negative patients with similar tumour burden 
[11, 12]. More than half of these tumours are diagnosed 
at an advanced stage [13] and only 50% of HPV-negative 
patients and 66% HPV-positive patients survive up to 5 
years post diagnosis (American Cancer Society, 2015). 
In addition, approximately 30% of HPV-positive patients 
develop recurrences within 2 years of initial diagnosis, 
whilst HPV-negative HNSCC patients show recurrences 
within 1 year [14]. For both tumour types when diagnosed 
early (before local and distant metastasis), the 5-year 
survival rate is 80% compared with only 15% in late 
diagnosis [15]. Given the clinical and biological diffrences 
between these two cancer types, it is therefore important 
to treat them separately when developing biomarkers [16].
Due to late diagnosis, the majority of HNSCC 
patients show either locally advanced disease and/or 
metastatic disease and require multimodality therapy 
which includes surgery, commonly followed by 
postoperative radiotherapy or chemo-radiotherapy [17]. In 
contrast, when detected early, these tumours are treated by 
single modality, surgery or radiotherapy alone, reducing 
the side effects of combining chemo-and radiotherapy. 
Therefore, there is an urgent need to develop early 
diagnostic biomarkers for the management of HNSCC 
patients [18].
MicroRNAs (miRNAs) are a new class of robust, 
small non-coding RNAs that regulate gene expression 
by binding to their mRNA targets [19–22]. The strong 
stability and altered expression levels of miRNA in 
biological samples (blood, saliva and urine) suggest that 
they could potentially be used as diagnostic, prognostic 
and predictive biomarkers for a number of tumour types 
[23, 24]. The field has moved away from using a single 
diagnostic biomarker to using multi-biomarker pannels 
[25, 26]. Multi marker panels are used to obtain an 
accurate overview of the tumour heterogeneity.
In a pilot study, we have previously demonstrated 
that three of the miRNAs from the nine panel can 
discriminate a healthy control group from a HNSCC 
patient group [27]. However, our previous data was 
generated using a small subet of samples, where the 
control group did not include smokers and ex-smokers 
and the patient group did not take into consideration the 
HPV status as well as the majority of the HNSCC patients 
were from an advanced stage of cancer. In contrast, the 
current study addresses these limitations and we have also 
included an additional four miRNAs, which have been 
preselected as these are upregulated in tumours tissue vs 
normal tissue (data obtained from The Cancer Genome 
Atlas) [28].
We hypothesised that the salivary miRNA panel 
can discriminate healthy controls from HPV-negative 
and HPV-positive patients as well as to differentially 
detect HPV-negative HNSCC patients from HPV-positive 
patients. The aims of this study were two-fold: (i) to 
identify salivary miRNAs that can discriminate a healthy 
control group from HPV-positive and HPV-negative 
HNSCC patients (ii) to identify salivary miRNAs that can 
differentially detect HPV-positive HNSCC patients from 
HPV-negative HNSCC patients.
RESULTS
Population characteristics
The mean age of controls was 44.7 years (SD 11.4, 
range 19–79 years), HPV-positive HNSCC patients was 
59.7 years (SD 11.4, range 37–87 years) and that of HPV-
negative HNSCC patients was 64.3 years (SD 10.38, range 
42–91 years). The two genders were equally represented 
in the control group but in the patient group, there were 
more men than women. Additionally, HNSCC patients 
were approximately twice as likely to be smokers or 
having quit within the past 12 month (61.4%) compared 
to controls (33.6%). Only 16.8% of HNSCC patients have 
never been smokers compared to 62.8% of controls. Most 
HPV-negative HNSCC patients were current smokers 
(85.1%) and the minority of them were former smokers 
(6.4%) while within the HPV-positive HNSCC patients, 
40.7% were current smokers and 35.2% former smokers. 
The majority of controls and HNSCC patients were 
Caucasians, 72.8% and 99%, respectively.
The clinical and pathological characteristics of 
HNSCC patients are shown in Table 1. The cancer sites 
were mostly of oropharyngeal and oral cavity (56.4% 
and 24.8% respectively), laryngeal and hypopharyngeal 
were 10.9% and 1% respectively; and 6.9% from other 
anatomical sites in the head and neck area. HPV-negative 
HNSCC patients had cancers within the oral cavity 
(42.6%) whereas the majority of HPV-positive HNSCC 
patients had cancers within the oropharynx (75.9%). HPV-
positive HNSCC patients were mostly diagnosed (83.3%) 
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Table 1: Participants demographic characteristics
Controls (n = 113) HPV-negative HNSCC patients (n = 47)
HPV-positive HNSCC 
patients
(n = 54)
Gender
 Male 59 (52.2) 34 (72.3) 49 (90.7)
 Female 54 (47.8) 13 (27.7) 5 (9.3)
Age (years)
 <50 73 (64.6) 5 (10.6) 10 (18.5)
 50 - 60 36 (31.9) 11 (23.4) 16 (29.6)
 >60 4 (3.5) 31 (65.9) 28 (51.9)
Race and ethnicity
 Caucasian 82 (72.6) 46 (97.9) 54 (100)
 Asian 13 (11.5) 1 (2.1) 0 (0)
 Other 18 (15.9) 0 (0) 0 (0)
Smoking status
 Smokers 38 (33.6) 40 (85.1) 22 (40.7)
 <10 9 (7.9) 6 (12.8) 3 (5.6)
 10-20 21 (18.6) 19 (40.4) 8 (14.8)
 >20 8 (7.1) 15 (31.9) 11 (20.4)
 Ex-smoker 4 (3.5) 3 (6.4) 19 (35.2)
 Non-smoker 71 (63.7) 4 (8.5) 13 (24.1)
Tumour characteristics
 AJCC Stage I 6 (12.8) 3 (5.6)
     Stage II 9 (19.1) 6 (11.1)
     Stage III 10 (21.3) 6 (11.1)
     Stage IVa 20 (42.6) 37 (68.5)
     Stage IVb 1 (2.1) 2 (3.7)
     Stage IVc 1 (2.1) 0 (0)
Tumour anatomic sites
 Oral cavity 20 (42.6) 5 (9.3)
 Oropharynx 16 (34.0) 41 (75.9)
 Larynx 9 (19.1) 2 (3.7)
 Hypopharynx 1 (2.1) 0 (0)
 Neck 1 (2.1) 6 (11.1)
Differentiation status
 Well differentiated 9 (19.1) 2 (3.7)
 Well to moderately 
differentiated 2 (4.3) 1 (1.9)
(Continued)
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with stages III and IV tumours, whilst 46.8% of HPV-
negative patients were diagnosed with stages III and IV 
tumours. This is primarily due to the higher frequency of 
patients with nodal neck disease that is commonly seen in 
HPV-positive HNSCC [29].
miRNA yields from small volumes of saliva 
samples
We have previously described a robust and a 
reproducible method to isolate high yields of miRNA from 
both fresh and archived saliva samples based on QIAzol 
(Qiagen, Valencia, CA, USA) extraction followed by solid 
phase enrichment of miRNAs on silica, column [27]. The 
amount of miRNAs isolated in 200 μL of saliva collected 
from healthy controls was 0.123 to 6.01 μg and from 
HNSCC patients was 0.21 to 19.3 μg yields.
Salivary miRNA expression levels can 
discriminate a control group from a HPV-
negative and a HPV-positive HNSCC patient 
group
We have performed both univariate and multivariate 
statistical analysis to determine the best miRNA that can 
detect HPV-positive and HPV-negative HNSCC patients. 
Univariate analysis of individual miRNA expression levels 
demonstrated that miRNA-9, -196a, -196b, -210, -222, 
and -455 were significantly upregulated in the saliva from 
HPV-negative HNSCC patients compared with saliva from 
healthy controls; whilst the expression levels of miRNA-9, 
-134, -196a, -196b, -210 and -455 were significantly 
upregulated in the saliva from HPV-positive HNSCC 
patients compared with healthy controls (Figure 1).
We have identified a combination of salivary 
miRNA-9, -127, -134, -191, -222 and -455 as the most 
parsimonious set of candidates for identifying HPV-
negative patients from healthy controls using multiple 
logistic regression analysis. This resulted in 60% 
sensitivity and 94% specificity. The combination of 
miRNA-9,-134, -210, and -455 and -196b was found to be 
the most appropriate for identifying HPV-positive patients 
from healthy controls. This resulted in a sensitivity of 65% 
and a specificity of 95% (see Table 2  and Figure 2).
Salivary miRNA expression levels can 
discriminate HPV-positive HNSCC patients from 
HPV-negative HNSCC patients
Using a Mann Whitney U test, the expression level 
of miRNA-210 was elevated in saliva collected from HPV-
negative HNSCC patients compared with HPV-positive 
HNSCC patients. Using multiple logistic regression 
analysis pipeline, we have identified the combination 
of miRNA-191, -196b, -210, and -222 to be the most 
parsimonious miRNA set for discriminating HPV-negative 
patients from HPV-positive patients.
Salivary miRNA expression levels could detect 
eraly stage HPV-negative and HPV-positive 
HNSCC pateints from a control group
The miRNA expression levels of -196a, -196b, -210 
and -455 were found to be elevated in the saliva collected 
from early clinical stages (stages I and II) HPV-negative 
HNSCC patients compared with the saliva from healthy 
controls using the Mann Whitney U test. Whilst the 
upregulation of miRNA-9, -127, -196a, -196b, -222 and 
-455 were found in the saliva collected from early stage 
(stages I and II) HPV-positive HNSCC patients compared 
with healthy controls (see Figure 3 and 4).
DISCUSSION
Despite advanced locoregional control and reduced 
treatment related morbidity, the five-year survival rates for 
Controls (n = 113) HPV-negative HNSCC patients (n = 47)
HPV-positive HNSCC 
patients
(n = 54)
 Moderately differentiated 16 (34.0) 12 (22.2)
 Moderately to poorly 
differentiated 5 (10.6) 7 (13.0)
 Poorly differentiated 6 (12.8) 13 (24.1)
 N/A 9 (19.1) 19 (35.2)
Keratinisation status
 keratinising 13 (27.7) 4 (7.4)
 non-keratinising 34 (72.3) 45 (83.3)
 others 0 (0) 5 (9.3)
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HPV-positive and HPV-negative HNSCC patients have not 
improved [30]. Diagnostic biomarkers are urgently needed 
to identify these patients earlier to improve survival rates 
and minimise the treatment toxicity. The rationale for 
improving prognosis and de-escalating therapy for disease 
diagnosed early is not only self-evident, it is applicable to 
virtually every cancer, and there is overwhelming literature 
evidence of better prognosis with earlier diagnosis in 
these patients [31, 32]. In this study, a multivariable 
logistic regression analysis with cross validation was 
used to identify the most robust salivary miRNAs that 
can discriminate a control group from HPV-negative and 
HPV-positive HNSCC patients as well as to differentially 
diagnose HPV-negative and HPV-positive patients. In this 
study, we have used a multimarker approach to minimise 
tumour heterogeneity and biological variability.
One of the major challenges in cancer research 
biomarker studies is to identify stable biomolecules 
Figure 1: The expression levels of nine miRNA in saliva collected from healthy control (n=113) as well as HPV-negative 
(n=47) and HPV-positive (n=54) by RT-qPCR.  SNORD-96A was used as a normerliser. Statistically significant differences were 
determined using Mann Whitney U Test. Significant differences are denoted as *P<0.05; **P<0.01; ***P<0.001 and ****P<0.0001.
Table 2: Discrimination of healthy controls from HPV-negative HNSCC patients and -positive HNSCC patients 
using the combined miRNA panels
Control vs HPV-patients Control vs HPV +patients
Probability threshold 0.45 0.41
Sensitivity 0.60 0.65
Specificity 0.94 0.95
Negative predictive value 0.85 0.85
Positive predictive value 0.82 0.87
AUC 0.82 0.80
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which can be routinely measured in easily accessible 
samples [33]. Robustness and reproducibility are key 
requisites prior to clinical implementation of biomarkers. 
To increase the robustness of the identified miRNA panel, 
we have used a pipeline consisting of multiple logistic 
regression with a ROC curve analysis and a 10-fold cross-
validation. We have used this statistical analysis method 
to increase the likelihood of clinical implementation of 
this miRNA panel, when it is applied to an independent 
cohort of patients and controls. This then reduces the risk 
of obtaining overly optimistic data and hence increases the 
likelihood of clinical translation.
Previous studies have shown that miRNA expression 
signatures are promising biomarkers for the diagnosis, 
prognosis and prediction of human cancers [34–39]. We 
have found elevated levels of miRNA-9 in saliva collected 
from HNSCC patients compared with saliva from controls, 
paralleling tumour tissue data for HNSCC [27, 28, 40–
42].  Similarily, the overexpression of miRNA-9 has been 
previously observed in many other cancer types including 
osteosarcoma, correlated significantly with poor prognosis 
as a result of tumor metastasis [43].
Salivary miRNA-134 expression levels showed 
concordance to the tumour expression levels [28]; the 
upregulation of miRNA-134 in tongue tumour tissues 
has shown to be associated with an increase in nodal 
metastasis as well as mortality in HNSCC patients 
mediated via the downregulation of WWOX gene [44]. In 
line with our salivary miRNA- 196a data, previous studies 
have also demonstrated an upregulation of miRNA-196a 
in HNSCC tissues when compared to normal tissues [45–
47], with miRNA-196 precursor shown to be predictive 
of overall survival and disease-free survival in HPV-
positive oropharyngeal cancer patients [48]. Similarly, 
miRNA-455 levels were elevated in saliva from HPV-
positive and HPV-negative patients, supported by other 
studies demonstrating an elavted expression levels in 
tumours from uvula, larynx, floor of mouth and tongue of 
HNSCC patients [28, 39, 49, 50].
Current diagnosis is usually made after clinical 
presentation of symptoms, and involves biopsy to confirm 
diagnosis, HPV status by p16INK4A immunostaining, 
and histological classification [9, 10]. These diagnostic 
methods are applied to advanced stage tumours with 
significant clinical presentation of symptoms. The 
treatment and clinical management also differs between 
HPV-negative and HPV-positive HNSCC patients. 
Therefore, it becomes important to discriminate between 
these patient groups to tailor therapy. We found that 
the expression levels of salivary miRNA-210 can 
differentiate between HPV-positive and HPV-negative 
HNSCC patients. In addition, infection of HPV-16/18 in 
organotypic raft cultures of vaginal keratinocytes increased 
the expression of miRNA-210 [51]. Moreover, it has been 
also reported that the expression levels of miRNA-127-
3p is decreased in HPV-positive patients tumour tissues 
compared with HPV-negative patints tumour tissues 
[52]. Regardless of HPV status, we found that miRNA-
196a, -196b and -455 were significantly overexpressed in 
saliva from HNSCC patients from early stages of tumour 
development (stages I and II). A previous study has shown 
that miRNA-196a plays an oncogenic role in HNSCC 
through deregulation of cell proliferation [47]. Similarly, 
another study has shown that elevated levels of miRNA-
Figure 2: The receiver operator characteristics curve analysis from the independent validation study using saliva (A) HPV-negative 
HNSCC patients vs controls (B) HPV-positive HNSCC patients vs controls.
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Figure 3: A set of six salivary miRNAs that can discriminate the early stage (Stages I&II) of HPV-positive HNSCC 
patients from the healthy control smoker and non-smoker group.  *P<0.05 and **P<0.01.
Figure 4: A set of four salivary miRNAs that can be used in discriminating healthy controls from the early stage 
(Stages I&II) of HPV-negative HNSCC patients.  Significant differences are *P<0.05 and ***P<0.001.
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455-5p was associated with poor prognosis [53]. Albeit, 
our data has been generated in a small cohort of patients 
from stages I and II, it implies that these miRNA may 
have prognostic value as biomarkers for early detection of 
HNSCC. Therefore, a further study should be conducted to 
verify the predictive potential of the above markers.
One of the limitations in the current study is the 
low sensitivity (~60%), in contrast to a high specificity 
of 90%, indicating that this panel is better suited as a 
screening tool [54]. In addition, age as a continouus 
variable may affect this panel. Current literature dipicts 
that miRNAs are the key regulators of aging and has 
shown a higher expression levels in the tissues collected 
from older people [55]. Intriguingly, the salivary 
miRNAs investigated in this study didn’t show any 
significant changes as a result of aging (data not shown). 
A lager cohort with the addition of other parameters (e.g. 
new miRNA or other clinical variables) is warranted for 
a further investigation.
In summary, we have identified two miRNA 
panels that can discriminate healthy controls from 
HPV-negative (sensitivity =60%; specificity =94%) and 
-positive HNSCC patients (sensitivity =65%, specificity 
=95%). Remarkably, the salivary miRNA data strongly 
correlated with published TCGA data using tumour 
tissues obtained from HNSCC patients (international 
studies). Therefore, we are confident that the miRNA 
expression changes in saliva can be used as a proxy to 
determine tumour progression. Our approach of using 
multiple logistic regression coupled to ROC analysis 
with cross-fold validation has allowed us to identify 
salivary miRNAs with minimal biological variations 
in a control and a patient cohort. This opens up new 
avenues for exploring the utility of salivary miRNAs as 
either diagnostic, prognostic indicators or to determine 
the response to treatment. A future multi-centre 
confirmatory study is warranted to test the diagnostic 
performance of these salivary miRNA prior to clinical 
implementation.
MATERIALS AND METHODS
Participants
Unstimulated whole mouth saliva samples were 
collected from healthy individuals, including smokers 
and non-smokers (n=113) with no previous history of any 
malignancies to the head and neck areas as well as from 
HPV-positive (n=54) and HPV-negative (n=47) HNSCC 
patients at various tumour nodal metastasis (TNM) clinical 
stages (stages II-IV) of cancer who presented to the Head 
and Neck Clinic at the Princess Alexandra Hospital, 
Woolloongabba, Australia. Patients with early stages 
of tumours (stages I-II) in general do not show either 
local and/or distant metastasis [56]. The participants’ 
demographics and clinical characteristics are shown in 
Table 1. This study was approved by the University of 
Queensland Medical Ethical Institutional Board [HREC 
No: 2014000679 and 2014000862] and the Queensland 
University of technology [HREC No: 1400000617 and 
1400000641] and by the Princess Alexandra Hospital 
Ethics Review Board [HREC Number: HREC/12/
QPAH/381]. All participants gave written informed 
consent before sample collection.
Saliva sample collection and processing
Whole mouth resting saliva samples were collected 
from volunteers while seated in an upright position. 
Volunteers were asked to rinse their mouths with drinking 
water to remove food debris. They were then asked to 
tilt their heads down and pool saliva in the mouth for 
2-5 minutes [57, 58] before drooling into sterile 50 mL 
Falcon tubes (Sarstedt, Australia). Saliva samples were 
transported to the laboratory on dry ice.
miRNA extraction and cDNA synthesis from 
saliva samples
The enrichment and isolation of miRNA from 
saliva samples was performed using the NucleoSpin 
miRNA kit (Machnery-Nagel, Germany) as previously 
published [27]. In brief, whole mouth saliva (200 μL) 
was added to 800 μL of QIAzol lysis reagent (Qiagen, 
Valencia, CA, USA). The samples were briefly vortexed 
and incubated for 5 minutes at room temperature, 200 
μL of chloroform was added and vortexed vigorously 
and incubated for a further 5 minutes at RT. Samples 
were then centrifuged at 10,000 x g for 10 minutes at 
4°C. An aliquot of the upper aqueous layer (800 μL) 
was transferred into a new micro centrifuge tube and a 
further 200 μL of chloroform was added and vortexed. 
Samples were then centrifuged again at 10,000 x g at 
4ºC. The upper aqueous layer containing total RNA was 
carefully removed (800 μL) and transferred into a new 
micro centrifuge Eppendorff tube and 200 μL of 100% 
ethanol was added. The solution containing total RNA 
was passed through Nucleospin column (blue ring) by 
centrifugation at 11,000 g for 30s at RT. The eluent was 
collected and 800 μL of MX buffer was added.
The sample was loaded onto a Nucleospin column 
(green ring) and centrifuged at 11,000 g for 30 s at RT. 
The columns were then washed with 600 μL of MW1 
buffer and centrifuged at 11,000 g for 30 s. The wash 
was repeated with 700 μL followed by 250 μL of MW2 
buffer and centrifuged at 11,000 for 30 s. The columns 
were then centrifuged at 11,000g for 2 mins to remove 
all traces of ethanol. The miRNA was eluted in 30 μL of 
RNase free Water. The quantity of the isolated miRNA was 
determined by a Nanodrop ND-1000 spectrophotometer 
(Thermo scientific Wilmington DE).
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The cDNA synthesis of isolated miRNA (with an 
input of 250 ng) was carried out using the miScript II 
RT Kit with the Hispec buffer (Qiagen, Valencia, CA, 
USA) according to the manufacturers’ instructions. In 
brief, the miRNAs were polyadenylated by polymerase A 
and transcribed into cDNA using oligo-dT primers, both 
processes took place in parallel in the same tube. The 
oligo-dT has a 3’degenerate anchor and a universal tag 
sequence on the 5’end allowing amplification of mature 
miRNA using real-time PCR. The polyadenylation and 
universal tag primer ensured that genomic DNA was not 
amplified and so it was not necessary to perform a DNase 
treatment in the samples.
Quantitative real-time RT-PCR (RT-qPCR) for 
nine miRNA panel
To validate the miRNA expression levels 
in saliva samples, the nine miRNA miScript™ 
primer PCR Assays (Qiagen, Valencia, CA, USA) 
were used. This miRNA PCR panel included: 
hsa-miRNA-210-5p (Cat. No. MS00003801); 
hsa-miRNA-222-3p (Cat. No. MS00007609); 
hsa-miRNA-134-3p (Cat. No. MS00031437); hsa-
miRNA-127-5p (Cat. No. MS00008575); hsa-miRNA-
191-5p (Cat. No. MS00003682); hsa-miRNA-9-5p 
(Cat. No. MS00010752); hsa-miRNA-196a-3p (Cat. 
No. MS00031563); hsa-miRNA-196b-3p (Cat. No. 
MS00031570) and hsa-miRNA-455-3p (Cat. No. 
MS00009744). Briefly, 3 ng cDNA was used as a 
template in PCR amplifications and PCRs were run in 
duplicate using miScript Syber green PCR master mix 
(Qiagen, Valencia, CA, USA). The PCR was performed 
using the QuantStudioTM 7 Flex Real-Time PCR System 
(Thermo Fisher Scientific, Rockford, ILUSA). The PCR 
reaction mixtures were incubated at 95°C for 15 min 
to activate hot start Taq DNA polymerase and this was 
followed by 40 cycles of 94°C for 15 s, 55°C for 30s 
and 70°C for 30s, monitored by melt curve analysis. The 
threshold value (Ct) was determined for each well and 
the Ct values were averaged for each gene according to 
the Minimum Information for Publication of Quantitative 
Real-Time PCR Experiments guidelines [59].
A panel of five miRNAs were also tested for 
suitability as normalisers for miRNAs detected in human 
saliva (see Supplementary Table 1a). These assays are wet-
benched validated miScript™ primer PCR Assays from 
Qiagen and included RNU6.2 (Cat. No. MS00033740); 
SNORD68 (Cat. No. MS00033712); SNORD72 (Cat. 
No. MS00033719); SNORD95 (Cat. No. MS00033726) 
and SNORD96A (Cat. No. MS00033733). We found that 
SNORD-96A demonstrated minimal Ct changes between 
saliva collected and analysed from healthy controls and the 
patients. As such SNORD96A was used as a normaliser 
in all subsequent work. The average relative expression 
(∆Ct) of each targeted miRNA in controls and patients is 
listed in Supplementary Table 1b.
Statistical analysis
The expression levels of individual miRNAs from 
HPV-negative and HPV-positive HNSCC patients and the 
healthy controls were compared using the non-parametric 
Mann Whitney U test, using GraphPad Prism 5 software 
version 5.03 (GraphPad Software Inc., USA). The clinical 
utility of miRNAs as biomarkers was investigated using 
R [60] and RWeka [61]. A logistic regression model 
was fitted using RWeka [61], with the patient status as 
the outcome variable and the miRNAs as explanatory 
variables. RWeka used a variable selection procedure 
based on the cross validation error for selecting the most 
parsimonious model. This model was then used in 10 runs 
of 10-fold cross validation using the “train” function of 
the “Caret” package [62]. Since each cross validation 
randomly creates 10 folds (splits) of the data, the 10 runs 
could be considered to be different replicates of the same 
procedure [63]. The reader is directed to the data mining 
book of Witten et al., (2011) for further information. 
For each of these 10 runs, the predictions of this model 
and the performance were created and evaluated using 
the “predict” and “performance” functions respectively 
of the ROCR package [63]. Several methods have been 
proposed for averaging the ROCs curves [64]. In this 
study, threshold averaging was used, since it averaged the 
curves at exactly the same thresholds.
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